Skip to main content
. 2019 Aug 14;10:909. doi: 10.3389/fphar.2019.00909

Figure 5.

Figure 5

Tyrosol-treated skeletal muscle cells’ secretome promotes vascular endothelial and smooth muscle cells proliferation capability suppressed by hyperglycemia. (A–B) Ratio of proliferative cells in HUVECs (A) and MOVAS cells (B) cultured with conditioned media collected from tyrosol-treated C2C12 cells. Proliferative cells were examined using EdU-incorporation assay; left, representative images; right, the quantitative results. (C–D) Ratio of proliferative cells in HUVECs (C) and MOVAS cells (D) cultured with conditioned media collected from tyrosol-treated C2C12 cells and treated with VEGFR inhibitor (Ki8751; final concentration, 2 nM) or PDGFR-β inhibitor (CP868596; final concentration, 0.3 µM). Proliferative cells were examined using EdU-incorporation assay; left, representative images; right, the quantitative results. Scale bars, 200 µm. All experiments were done by subjecting the cells into hypoxia. Quantification data were expressed as mean ± SD (n = 6; *P< 0.05, **P < 0.01); CM-C, conditioned medium derived from C2C12 cells treated with PBS under normoglycemia; CM-H, conditioned medium derived from C2C12 cells treated with PBS under hyperglycemia; CM-H/Tyr, conditioned medium derived from C2C12 cells treated with tyrosol under hyperglycemia.